単施設で治療されたII期結腸癌患者における補助療法の指標としての高リスク因子の同定 by 山口 圭三
ONCOLOGY LETTERS  6:  659-666,  2013
Abstract. Although post-operative adjuvant chemotherapy 
(ACT) is only recommended for patients with stage II colon 
cancer who are at a high risk of recurrence, the definition 
of high risk remains unclear. The present study aimed to 
identify the risk factors for recurrence, which may also be 
indicators for adjuvant therapy, using a retrospective analysis 
of clinicopathological data obtained from stage II colon 
cancer patients who had undergone a curative resection. The 
present study also investigated the effects of ACT in patients 
who displayed the risk factors for recurrence. Univariate and 
multivariate analyses of the data collected from 377 stage II 
colon cancer patients, treated at Kurume University Hospital 
(Fukuoka, Japan) between 1982 and 2005, was conducted in 
order to determine and compare the risk factors for recur-
rence between the 163 patients who had undergone adjuvant 
therapy and the 214 patients who had not undergone adjuvant 
therapy. The risk factors for recurrence in patients who had 
not undergone adjuvant therapy were a serum carcinoembry-
onic antigen (CEA) level that was twice the cut-off value and 
pre-operative bowel obstruction. Adjuvant therapy provided 
no benefit to patients who presented with neither risk factor, 
but significantly decreased the recurrence rate in patients 
presenting with one or both risk factors. Based on these 
findings, serum CEA levels of twice the cut‑off value and 
pre-operative bowel obstruction were proposed as indica-
tors in the assessment for adjuvant chemotherapy following 
a curative resection for stage II colon cancer. These results 
warrant further clinical study of ACT in patients with one or 
both risk factors. 
Introduction
The current guidelines to treat stage II colon cancer patients 
include the recommendation that post-operative adjuvant 
chemotherapy (ACT) should only be considered for patients 
who have a high risk of recurrence (1,2). Although the defini-
tion of high risk has not been completely established to date, 
various risk factors have been proposed. The current American 
Society of Clinical Oncology (ASCO) Guidelines recommend 
the provision of ACT for patients with inadequately-sampled 
nodes, T4 lesions, tumor perforation or poorly-differentiated 
histology (3). The current European Society for Medical 
Oncology (ESMO) Clinical Practice Guidelines define 
patients with stage II colon cancer to be at high risk and a 
candidate for adjuvant therapy if at least one of the following 
characteristics are identified: Lymph nodes sampling <12; a 
poorly‑differentiated tumor; vascular, lymphatic or perineural 
invasion; tumor presentation with obstruction or tumor perfo-
ration; and pT4 stage (4).
In accordance with the ASCO and ESMO guidelines, the 
current Japanese guidelines for the treatment of colorectal 
cancer recommend adjuvant therapy for patients at a high risk 
of recurrence (5). Based on extensive research, the Japanese 
Study Group for Post-operative Follow-up of Colorectal 
Cancer, a multicenter collaborative study group, recently 
recommended ACT for patients who meet two or more of the 
following criteria: Extensive venous invasion; <13 dissected 
lymph nodes; an age of >50 years; and/or being of the male 
gender (6). In a previous examination of stage II colon cancer 
patients, it was identified that the patients who had presented 
with invasive gross tumors and elevated pre-operative serum 
carcinoembryonic antigen (CEA) levels and who had not under-
gone ACT were at a high risk of recurrence (7). Accordingly, 
in the present study, the patients with elevated pre-operative 
serum CEA levels were identified as candidates for ACT. The 
majority of studies conducted prior to the present study were 
based on a comparison of data that was collected from patients 
who had or had not undergone ACT. As a result, the effect of 
chemotherapy was not excluded as a confounding factor in the 
analysis of risk factors for recurrence. In addition, the effect of 
age or gender, which may not be associated with the malignant 
potential of colon cancer, cannot be excluded in the analysis of 
prognostic factors in terms of overall survival (OS), commonly 
used in past studies. To address these limitations, the time to 
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recurrence (TTR), a relatively objective measure, was used to 
determine the prognosis of the stage II colon cancer patients 
who had not undergone ACT following a successful curative 
resection, and to compare the prognosis with that of patients 
who had undergone adjuvant therapy in order to identify the 
risk factors for recurrence that may be indicators for adjuvant 
therapy (8).
Materials and methods
Patients and specimens. The present retrospective study 
examined data collected from 377 patients who were treated 
at a single medical institution (Kurume University Hospital, 
Kurume, Fukuoka, Japan) between 1982 and 2005 for stage II 
colon cancer. All patients met the study criteria of i) having been 
pathologically diagnosed with stage II colon cancer, ii) having 
undergone a curative resection with lymphadenectomy and 
iii) not having undergone pre-operative chemotherapy, radio-
therapy or immunotherapy. Of these 377 patients, 163 had 
undergone ACT and thus constituted the ACT group and 
214 patients had not undergone ACT and thus constituted the 
surgery alone (SA) group. The primary reasons as to why ACT 
had not been administered were refusal to provide informed 
consent and the patient age being ≥75 years. Approval for the 
study was obtained from the Kurume University Hospital 
Ethics Committee.
Diagnosis and staging procedures. The pathological factors 
and stage classification of colon cancer were determined 
according to the TNM classification system developed by the 
International Union against Cancer (UICC) (9). Mesenteric 
lymph nodes had been removed from the mesenteric adipose 
tissue for histological examination immediately after surgery. 
A pathological examination of all isolated lymph nodes was 
performed, with the histopathological examination being 
performed using a 5-mm thick longitudinal whole tissue 
section. Lymphatic permeation and venous invasion was 
determined on the basis of previously defined criteria (10,11). 
ACT. Oral fluoropyrimidines, including tegafur plus uracil 
(UFT; 300 mg/day per 1 m2 body area) and doxifluridine 
(5'‑DFUR; 600 mg/day per 1 m2 body area), an intermediate 
metabolite of capecitabine, were the agents that were adminis-
tered during a course of post-operative ACT that was provided 
for >6 months. 
Follow‑up schedule and examinations. All patients were 
monitored as outpatients according to a regular examination 
schedule. The final follow‑up date for the present study was 
April 30, 2011. The post-operative surveillance consisted of 
measuring the tumor marker levels, chest radiography and 
abdominal ultrasonography, in addition to a physical examina-
tion every 3 to 6 months for the first 3 years, every 6 months for 
the next 4 years and annually thereafter. Chest and abdominal 
computed tomography or magnetic resonance imaging was 
performed every 6 to 12 months for the first 3 years and then 
annually or when recurrence was suspected thereafter.
Statistical analysis. The TTR was calculated using the day 
of the first surgery as the start date and considering recur-
rence of the primary cancer or mortality due to the primary 
cancer as an event. TTR curves were then generated using 
the Kaplan-Meier method and the significance between 
groups was determined using the log-rank test. Univariate 
and multivariate analyses of the clinicopathological factors, 
including the CEA level associated with the TTR, were 
performed using Cox's proportional hazards model. The 
analysis of the differences in the clinicopathological factors 
between the groups was performed using Fisher's exact test 
and Student's t-test. All statistical analyses were performed 
using JMP version 9.0.2 software (SAS Institute, Inc., Cary, 
NC, USA) and P<0.05 was considered to indicate a statisti-
cally significant difference. 
Results
Patient clinicopathological data. The clinicopathological 
data of the patients are presented in Table I. The tumors were 
located in the left colon (descending, sigmoid or rectosigmoid 
colon) in 225 patients and the right colon (cecum, ascending 
colon or transverse colon) in 152 patients. The classification 
of the tumor according to the gross tumor type was invasive 
in 39 patients and non-invasive in 338 patients. An increased 
pre-operative CEA level was observed in 136 patients (36.1%), 
25 (18.4%) of who later experienced recurrence. In addi-
tion, a CEA level of twice the cut-off value was observed in 
68 patients (18.0%), 15 (22.1%) of whom later experienced 
recurrence (Table II). The tumor diameter was greater than 
the median tumor diameter of 55 mm in 203 patients.
Among the total patients, there were 337 in whom 
≥12 lymph nodes had been sampled and the histological exam-
ination indicated that the tumor was well-differentiated in 
276 patients, moderately-differentiated in 64 and poorly-differ-
entiated/other in 37. A total of 25 patients were diagnosed with 
a pre‑operative bowel obstruction; these patients were defined 
as those who required the placement of an oral or transanal 
decompression tube or had undergone emergency surgery 
for pre-operative bowel obstruction. Perforations had been 
observed in two of these patients, who were therefore included 
in the group of patients with bowel obstructions. Extensive 
lymphatic permeation was observed in 45 patients and exten-
sive venous invasion in 33 patients.
The overall median follow-up duration was 98 months. 
Recurrence was observed in 48 patients (12.7%), of whom 
14 (8.6%) were in the ACT group and 34 (15.9%) were in the SA 
group. A statistical analysis of the results indicated a signifi-
cant difference between the two groups in terms of recurrence 
(P=0.042; Table II), age (P=0.001), number of dissected lymph 
nodes if <12 nodes had been sampled (P=0.006) and the extent 
of venous invasion (P=0.026; Table I).
Univariate and multivariate analyses. The results of the 
univariate analysis, which used Cox's proportional hazards 
model to examine the TTR of the SA group, revealed that 
the CEA levels were twice the cut-off value and that bowel 
obstruction and extensive lymphatic permeation were signifi-
cant risk factors for recurrence (Table III). The statistical 
analysis of the significance of a CEA level above the cut‑off 
value, twice the cut-off value and three times the cut-off 
value indicated that a level that was twice the cut-off value 
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had the highest hazard ratio (HR) and the least significant 
association. Therefore, a CEA level of twice the cut-off 
value was used in the subsequent analyses. The multivariate 
analysis of the parameters that were identified as significant 
in the univariate analysis confirmed that a CEA level of twice 
the cut‑off value and bowel obstruction were significant risk 
factors for recurrence.
Effect of ACT on patients with risk factors for recurrence. 
Subsequent investigation of the effect of post-operative ACT 
Table I. Comparison of patient data by treatment group.
Variable ACT group SA group P-value
Age, years (mean ± SD) 63.3±9.4 67.7±11.7 0.001a
Gender, n
  Male 104 141 0.744
  Female   59   73
Tumor location, n
  Left colon   96 129 0.832
  Right colon   67   85
Gross tumor type, n
  Invasive   19   20 0.498
  Non-invasive 144 194
Pre-operative CEA level, n 
  ≥NL   56   80 0.448
  <NL 107 128
Pre-operative CEA level, n 
  ≥NLx2   30   38 0.999
  <NLx2 133 170
Pre-operative CA19-9 level, n 
  ≥NL   12   20 0.690
  <NL   55 73
Tumor size, n
  ≥Median   96 107 0.096
  <Median   67 107
Number of dissected LNs, n
  <12     9   31 0.006a
  ≥12 154 183
Histology, n
  Others   19   18 0.301
  Well/mod 144 196
T factor
  T4   63   74 0.450
  T3 100 140
Adjacent organ invasion, n
  Positive   19   23 0.869
  Negative 144 191
Bowel obstruction, n
  Positive   10   15 0.836
  Negative 153 199
Lymphatic permeation, n
  Extensive   20   25 0.874
  Slight 143 189
Venous invasion, n
  Extensive     8   25 0.026a
  Slight 155 189
Significance was evaluated using the Fisher's exact and Student's t‑tests; aP<0.05. ACT, adjuvant chemotherapy; CA19‑9, carbohydrate antigen 19‑9; CEA, car-
cinoembryonic antigen; LN, lymph node; mod, moderately‑differentiated adenocarcinoma; NL, normal limit; SA group, surgery alone; well, well‑differentiated 
adenocarcinoma.
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in patients with the previously mentioned risk factors for 
recurrence showed no significant differences in the recur-
rence rate in patients with and without a CEA level of twice 
the cut-off value in the ACT group (P=0.999). However, the 
recurrence rate was significantly higher in patients with a CEA 
level of twice the cut-off value in the SA group (P=0.003). In 
Table II. Comparison of patient data by recurrence status.
Variable Recurrent cases Non-recurrent cases P-value
Age, years (mean±SD) 66.0±11.8 65.8±10.8 0.927
Gender, n
  Male 34 211 0.420
  Female 14 118
Tumor location, n 
  Left colon 33 192 0.208
  Right colon 15 137
Gross tumor-type, n
  Invasive   9   30 0.070
  Non-invasive 39 299
Pre-operative CEA level, n
  ≥NL 25 111 0.024a
  <NL 23 212
Pre-operative CEA level, n
  ≥NLx2 15   53 0.026a
  <NLx2 33 270
Pre-operative CA19-9 level, n
  ≥NL   3   29 0.385
  <NL   6 122
Tumor size, n
  ≥Median 24 179 0.643
  <Median 24 150
Number of dissected LNs, n
  <12   7   33 0.321
  ≥12 41 296
Histology, n
  Others   5   32 0.799
  Well/mod 43 297
T factor, n
  T4 18 119 0.873
  T3 30 210
Adjacent organ invasion, n
  Positive   9   33 0.085
  Negative 39 296
Bowel obstruction, n
  Positive   6   19 0.112
  Negative 42 310
Lymphatic permeation, n
  Extensive 10   35 0.055
  Slight 38 294
Venous invasion, n
  Extensive   7   26 0.165
  Slight 41 303
Treatment, n
  SA 34 180 0.042a
  ACT 14 149
Significance was evaluated using the Fisher's exact test and Student's t‑test. aP<0.05. ACT, adjuvant chemotherapy; CA19‑9, carbohydrate antigen 19‑9; CEA, carcino-
embryonic antigen; LN, lymph node; mod, moderately‑differentiated adenocarcinoma; NL, normal limit; SA, surgery alone; well, well‑differentiated adenocarcinoma.
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addition, the rate of recurrence in patients in the ACT group 
who had presented with a CEA level of twice the cut-off value 
was identified to be significantly lower than that of patients in 
the SA group (P=0.008; Table IV). 
No significant differences were identified in the rate of 
recurrence between patients in the ACT group who were and 
who were not diagnosed with a pre-operative bowel obstruc-
tion (P=0.999). In contrast, within the SA group, the rate of 
recurrence was shown to be significantly higher in patients 
who were diagnosed with pre-operative bowel obstructions 
than in those who were not (P=0.018; Table V). A comparison 
of the patients in the ACT and SA groups who were diagnosed 
with a pre-operative bowel obstruction revealed that the rate 
of recurrence of the patients in the ACT group was lower than 
that of the patients in the SA group (P=0.051; Table V).
A multivariate analysis confirmed that a CEA level of 
twice the cut-off value and a diagnosis of a pre-operative 
bowel obstruction were significant factors in predicting the 
rate of recurrence. Based on these results, the 377 patients 
were divided into two groups. Those who had presented with 
at least one of the risk factors (CEA level of twice the cut-off 
value and/or a diagnosis of a pre-operative bowel obstruction) 
were assigned to the high-risk group (n=86) and those who had 
presented with neither risk factor were assigned to the low-risk 
group (n=291). A between-group comparison, which calculated 
the TTR using the Kaplan‑Meier method, revealed a signifi-
cantly lower rate of recurrence in the low-risk group (Fig. 1). 
Table III. Univariate and multivariate analyses of the TTR of the SA group.
  Univariate analysis   Multivariate analysis
 --------------------------------------------------------------------------- ---------------------------------------------------------------------------
Variable HR 95% CI P-value HR 95% CI P-value
Age (≥75 years vs. <75 years) 1.561 0.760‑3.087 0.218
Gender (male vs. female) 1.556 0.753-3.527 0.240
Tumor location (left vs. right colon) 1.177 0.592-2.457 0.647
Gross tumor-type (invasive vs. non-invasive) 2.518 0.941-5.684 0.064
CEA (≥NL vs. <NL) 2.324 1.183‑4.649 0.015a
CEA (≥NLx2 vs. <NLx2) 3.353 1.513‑7.165 0.004a 3.840 1.674-8.629 0.002a
CEA (≥NLx3 vs. <NLx3) 2.958 1.349‑6.013 0.008a
CA19‑9 (≥NL vs. <NL) 1.828 0.262‑8.496 0.492
Tumor size (≥ median vs. <median) 0.765 0.383‑1.503 0.437
Number of dissected lymph nodes (<12 vs. >12) 1.898 0.760‑4.132 0.158
Histology (others vs. well/mod) 0.983 0.236-2.751 0.977
T factor (T4 vs. T3) 1.059 0.496-2.129 0.876
Bowel obstruction (yes vs. no) 3.482 1.301-7.859 0.016a 6.284 2.024-16.47 0.003a
Lymphatic permeation (extensive vs. slight) 2.720 1.150-5.748 0.025a 2.523 0.911-6.017 0.072
Venous invasion (extensive vs. slight) 1.654 0.562-3.923 0.328
aP<0.05. TTR, time to reccurrence; CA19‑9, carbohydrate antigen 19‑9; CEA, carcinoembryonic antigen; CI, confidence interval; HR, hazard ratio; mod, 
moderately‑differentiated adenocarcinoma; NL, normal limit; SA, surgery alone; well, well‑differentiated adenocarcinoma.
Table IV. Correlation between serum CEA levels of twice the cut-off value and recurrence.
  ACT groupa SA groupb
 --------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------
CEA ≥NLx2c <NLx2 ≥NLx2c <NLx2
Recurrence
  Yes, n (%) 2 (6.7) 12 (9.0) 13 (34.2) 21 (12.4)
  No, n (%) 28 (93.3) 121 (91.0) 25 (65.8) 149 (87.6)
Significance was evaluated using Fisher's exact test; aP=0.999, bP=0.003, cP=0.008. ACT, adjuvant chemotherapy; CEA, carcinoembryonic antigen; NL, normal 
limit; SA group, surgery alone.
Table V. Correlation between bowel obstruction and recur-
rence.
  ACT groupa SA groupb
  ----------------------------------------- ----------------------------------------
Bowel obstruction Yesc No Yesc No
Recurrence
  Yes, n (%) 0 (0.0) 14 (9.2) 6 (40.0)   28 (14.1)
  No, n (%) 10 (100) 139 (90.8) 9 (60.0) 171 (85.9)
Significance was evaluated using Fisher's exact test; aP=0.999, bP=0.018, 
cP=0.051. ACT, adjuvant chemotherapy; SA, surgery alone.
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A within-group analysis of the low-risk group indicated no 
significant differences in the rate of recurrence between the 
low-risk patients in the ACT and SA groups (Fig. 2). However, 
the within‑group analysis indicated a significantly lower risk 
in the high-risk patients in the ACT group than in the high-risk 
patients in the SA group (Fig. 3).
Discussion
Patients with stage II colon cancer who are only treated with 
surgery are generally considered to have a better prognosis if a 
curative resection is possible. Previous studies have estimated 
the recurrence and 5-year OS rates following the treatment of 
stage II colon cancer to be 7.9-22 and 75-92.5%, respectively, 
and have shown that ~20% of patients experience recurrence 
within 5 years (1,12,13). In Japan, the recurrence and 5-year 
OS rates are estimated to be 13.3-13.8 and 83.7%, respec-
tively (6,14). While these rates are comparable with the 12.7 
and 82.6% rates identified for recurrence and OS, respectively, 
in the present study, when all the patients were analyzed, the 
rates did not reflect the significant differences in the recurrence 
and 5-year OS rates between patients in the ACT group (8.6% 
and 91.0%) and the SA group (15.9% and 76.1%; P<0.0001). 
Although the improved prognosis of the ACT group may have 
been due to selection bias, identifying the high-risk factors for 
recurrence is fundamental for determining the form of adju-
vant therapy that is most likely to be effective.
Among the various endpoints that may be used in a study 
of adjuvant therapy, Punt et al recommended the use of the 
disease-free survival (DFS) rate as the primary endpoint 
and the TTR as the secondary endpoint (8). However, as the 
present study aimed to identify the high-risk factors for recur-
rence, the TTR was used as the endpoint instead of DFS or OS 
rates to exclude the effect of mortality due to other causes or 
other cancers. With regard to the correlation between prog-
nosis and gender, previous studies have revealed that while 
there are no significant differences in OS or disease‑specific 
survival (DSS) rates between male and female colon cancer 
patients (15,16), male colon cancer patients have a poorer 
prognosis (6,17‑19), experience a significantly higher rate of 
post-operative mortality and are more likely to succumb to 
adverse cardiovascular events (17). These findings indicate that 
colon tumors have the same biological malignant potential in 
male and female patients, but that males are more vulnerable 
to surgical stress (16). Nevertheless, female colorectal cancer 
patients have also been identified to have a poor prognosis (19), 
and thus a consensus remains to be achieved with regard to 
the correlation between gender and prognosis. With regard 
to the correlation between prognosis and age, elderly patients 
have been identified to have low rates of survival, which has 
been attributed to the consideration of all mortalities as events 
and the low rate of administration of adjuvant therapy to this 
population (16). However, such attribution is controversial, as a 
poor prognosis has also been reported in younger patients (20).
In the case of all events, gender and age are highly likely 
to affect the inherent biological behavior of the patient, rather 
than any difference in the biological malignant potential of 
the tumor. It is thus unclear whether gender and age should be 
considered high‑risk factors, simply as statistically significant 
differences have been observed between males and females 
and among various age groups. Based on this reasoning, the 
TTR was considered a more acceptable measure in the present 
analysis of the risk of recurrence than the OS or DFS rates, for 
which gender or age may have been a confounding risk factor.
In a previous study on stage II colon cancer patients, the 
invasive gross tumor type, elevated pre-operative serum CEA 
level and lack of adjuvant therapy were identified as risk factors 
for a shorter relapse-free survival (7). However, as the patients 
in the ACT group had shown a better prognosis than those 
in the SA group, regardless of whether the patients presented 
with a normal or elevated pre-operative CEA level, the CEA 
level was considered to be a significant factor in the assess-
Figure 3. Time to recurrence (TTR) curves of high-risk patients. ACT, adju-
vant chemotherapy; SA, surgery alone.
Figure 1. Time to recurrence (TTR) curves of all patients by risk group.
Figure 2. Time to recurrence (TTR) curves of low-risk patients. ACT, adju-
vant chemotherapy; SA, surgery alone.
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ment of indication for post-operative ACT. In contrast, a CEA 
level of twice the cut-off value and a diagnosis of pre-operative 
bowel obstruction were identified as independent factors for a 
shorter TTR in the present study. 
Previous studies have identified several pathological factors, 
including gross tumor type (6,7), depth of invasion (21-23), 
tumor histology (23) and vascular invasion (6,21,23), and 
surgical factors, including the number of dissected lymph 
nodes (6,22), as high-risk factors in stage II colon cancer. 
Researchers generally interpret the results that are associated 
with the risk factors that are assessed objectively, including 
age and gender, in a similar manner. However, the results 
with regard to the pathological risk factors that are assessed 
subjectively, including tumor histology and vascular invasion, 
as well as those regarding the gross tumor type and number 
of dissected lymph nodes, may be interpreted in a different 
manner. To avoid inconsistent interpretations of the present 
results, a serum CEA level of twice the cut-off value and a 
diagnosis of pre-operative bowel obstruction, which are indi-
cators that are relatively objective and reflective of a high risk 
prior to surgery, were used in the analysis of the TTR in the 
present study. 
Several studies have also considered pre-operative bowel 
obstruction to be a risk factor for recurrence in stage II colon 
cancer patients (23-25). However, as these studies often used 
various definitions of pre-operative bowel obstruction, leading 
to wide variations in the rate of obstruction of between 9.8 and 
47% (23‑26), it is difficult to assess the utility of this symptom 
as a risk factor. Pre-operative bowel obstruction is generally 
defined using clinical signs, including arrested flatus/bowel 
movement, abdominal distension and vomiting and radiolog-
ical findings, such as intestinal dilatation (23). The incidence of 
pre-operative bowel obstruction among the patients examined 
in the present study was 7.0%, a lower incidence than reported 
in previous studies. This finding may be attributed to the use 
of a more restrictive and objective definition of bowel obstruc-
tion; specifically, bowel obstruction was diagnosed if patients 
required emergency decompression via placement of a decom-
pression tube or emergency surgery. This is a more objective 
means of assessment compared with the evaluation of clinical 
signs and radiological findings. Generally, patients with colon 
cancer who develop pre-operative bowel obstructions tend to 
experience distant metastasis. Although the mechanism by 
which metastasis develops is unclear (23), infiltration of micro 
tumor cells into the lymphatic vessels or veins and circulation 
due to increased intestinal pressure have been hypothesized.
CEA is a glycoprotein that was discovered by Gold and 
Freedman in 1965 and is present in the digestive tract of the 
fetus and the tumor tissue of endodermally-derived diges-
tive organs (27). Although CEA was once considered to be a 
specific marker for gastrointestinal cancer, it is now recognized 
as a more general tumor marker. The pre-operative CEA level 
is now known to be associated with prognosis (7,21,28-30). 
Although a number of studies have established the cut-off value 
between a normal and high CEA level as 5 ng/ml (7,21,28), 
others have observed it to range between 10 ng/ml (29) and 
15 ng/ml (30). In an experimental model, a CEA-producing 
tumor was identified to be more capable of liver metastasis 
than a non-CEA-producing tumor (31). Therefore, the higher 
the CEA level, the higher the malignant potential of the tumor. 
Patients with an elevated pre-operative CEA level may display 
micrometastases, particularly in the liver. 
The 2006 ASCO Guidelines indicate that a pre-operative 
serum CEA level of >5 ng/ml is associated with a poor prog-
nosis. However, this factor has not been adopted as an indicator 
for the assessment of indication for post-operative ACT due to 
insufficient data to support its use (32). Although the previous 
ESMO Clinical Practice Guidelines indicated a high serum 
CEA level as a high-risk factor for stage II colon cancer (33), the 
latest guidelines do not (4). As such, it remains controversial to 
consider a high CEA level as a high-risk factor or as an indicator 
for ACT. Nevertheless, using CEA levels offers the advantage of 
objectivity in an assessment, as an objective indicator is unlikely 
to be assessed differently by various interpreters. 
Based on these previous findings and indications, we 
propose that stage II colon cancer patients who have undergone 
a curative resection should be considered to be at a high risk 
for recurrence if they present with a pre-operative CEA level 
of twice the cut-off value and/or with a pre-operative bowel 
obstruction. In the present study, patients in the low-risk group 
(n=291) who had presented with neither indicator were shown 
not have benefited from adjuvant therapy. In contrast, the 
patients in the high-risk group (n=86), who presented with one 
or both indicators and had undergone adjuvant therapy were 
shown to have experienced a significantly improved prognosis 
than those in the high-risk group who had not undergone adju-
vant therapy; this was manifested by the 5‑year recurrence‑free 
rate of 94.4% observed in the ACT group compared with 71.1% 
identified in the AS group. In accordance with the proposal 
and results of the present study, patients who present with a 
pre-operative serum CEA level of twice the cut-off value or 
with a pre-operative bowel obstruction should be considered 
as candidates for adjuvant chemotherapy. Future studies into 
the prognostic risk factors for stage II colon cancer should 
examine the validity of this proposal by conducting a prospec-
tive investigation of the benefit of ACT for stage II colon cancer 
patients who present with the two proposed high-risk factors. 
Further research should also build on the findings using stan-
dard procedures at a single institution to obtain objective data 
to examine the correlation between prognosis and a variety of 
clinicopathological factors.
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